A6FB1BEE-0D36-480C-8619-1FA82583FCD1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 21.353482260183966
- age_years
- 27
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.517
- MYC_TARGETS_V2+0.505
- DNA_REPAIR+0.490
- OXIDATIVE_PHOSPHORYLATION+0.486
- UNFOLDED_PROTEIN_RESPONSE+0.446
- NOTCH_SIGNALING+0.377
- PROTEIN_SECRETION+0.363
- TGF_BETA_SIGNALING+0.297
- ADIPOGENESIS+0.285
- WNT_BETA_CATENIN_SIGNALING+0.260
Top 10 suppressed
- KRAS_SIGNALING_DN-0.381
- INFLAMMATORY_RESPONSE-0.270
- COAGULATION-0.240
- SPERMATOGENESIS-0.239
- MYOGENESIS-0.227
- ESTROGEN_RESPONSE_LATE-0.214
- ANGIOGENESIS-0.205
- IL6_JAK_STAT3_SIGNALING-0.186
- COMPLEMENT-0.178
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.159
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.924 |
| 2 | 0AF0D126-507C-4DE1-B9A2-A1B8F0A089FB | — | — | 0.902 |
| 3 | 635170D3-D669-4165-B69C-9C9A246BFF11 | — | — | 0.897 |
| 4 | 743F5644-F650-437A-B4AE-4972F88606D8 | — | — | 0.882 |
| 5 | 7AE107A7-8EA7-4920-A579-2337C007920D | — | — | 0.880 |
| 6 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.873 |
| 7 | 72781523-C5BA-4B54-8410-E238B5F441B4 | — | — | 0.870 |
| 8 | 194676E1-632C-4B99-A9C8-80E36DD6C85E | — | — | 0.869 |
| 9 | EA6A086B-F655-47E8-9E70-8A2D36FC2AE1 | — | — | 0.855 |
| 10 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.517 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.505 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.490 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.486 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.446 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.377 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.363 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.297 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.285 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.216 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.199 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.196 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.194 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.192 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.169 | Inavolisib | — uncovered |
| APOPTOSIS | 0.167 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.148 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.144 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |